Clinical Trial
Open-label Study to Determine the Maximum Tolerated Dose of DSG3-CAART in Mucosal-dominant PV Patients (mPV)
Investigator
Complete title:
A phase 1, open-label, safety and dosing study of autologous desmoglein 3 chimeric autoantibody receptor T cells (DSG3-CAART) in subjects with active, anti-DSG3, mucosal-dominant pemphigus vulgaris
Trial phase:
Phase
I
Study ID:
NCT04422912
Local study ID:
RG1121092
Summary:
Mucosal-dominant pemphigus vulgaris (mPV) is a B-cell mediated autoimmune disorder in which painful blisters are formed on the mucosal membrane, including the mouth, nose, throat, eyelids, anus, and genitals. This phase 1 study is being conducted to find the maximum tolerated dose and optimal fractionated infusion schedule of an investigational cell therapy, DSG3-CAART, that can be given to patients with mPV who are inadequately managed by standard therapies. DSG3-CAART may potentially lead to complete and durable remission of disease.
Trial keywords:
Immunotherapy
Enrollment status:
Recruiting
Trial eligibility
** For eligibility information, please click on the "Look up trial at NIH" link above **
Other eligibility criteria may apply.
Other eligibility criteria may apply.
Trial exclusions
** For exclusion information, please click on the "Look up trial at NIH" link above **
Other exclusion criteria may apply.
Learn more
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact us
For more information about Fred Hutch and to schedule an appointment.
